Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antje Hoering

Showing results (1-10 of 74) with videos related to

Pageof 8
Sort By:
Clinical Advances in Hematology & Oncology : H&O|July 4, 2007
Clinical trial designs for multiple myelomaAntje Hoering, John Crowley
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2010
Seamless phase I-II trial design for assessing toxicity and efficacy for targeted agentsAntje Hoering, Mike LeBlanc, John Crowley
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Randomized phase III clinical trial designs for targeted agentsAntje Hoering, Mike Leblanc, John J Crowley
Clinical Trials (London, England)|March 27, 2013
Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agentsAntje Hoering, Alan Mitchell, Michael LeBlanc, et al.
Statistics in Medicine|July 11, 2003
On the analysis of viral load endpoints in HIV vaccine trialsMichael G Hudgens, Antje Hoering, Steven G Self
Future Oncology (London, England)|April 12, 2017
End points and statistical considerations in immuno-oncology trials: impact on multiple myelomaAntje Hoering, Brian Durie, Hongwei Wang, et al.
Cancer Research|April 19, 2005
Experimental design and analysis of antibody microarrays: applying methods from cDNA arraysJeanette E Eckel-Passow, Antje Hoering, Terry M Therneau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120Madhav V Dhodapkar, Rachael Sexton, Antje Hoering, et al.
Haematologica|August 30, 2008
Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapyGuido Tricot, Bart Barlogie, Maurizio Zangari, et al.
Blood Advances|July 6, 2022
Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman diseaseFrits van Rhee, Adam Rosenthal, Karan Kanhai, et al.
Pageof 8

Showing results (1-10 of 74) with videos related to

Sort By:
Pageof 8
Clinical Advances in Hematology & Oncology : H&O|July 4, 2007
Clinical trial designs for multiple myelomaAntje Hoering, John Crowley
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2010
Seamless phase I-II trial design for assessing toxicity and efficacy for targeted agentsAntje Hoering, Mike LeBlanc, John Crowley
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Randomized phase III clinical trial designs for targeted agentsAntje Hoering, Mike Leblanc, John J Crowley
Clinical Trials (London, England)|March 27, 2013
Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agentsAntje Hoering, Alan Mitchell, Michael LeBlanc, et al.
Statistics in Medicine|July 11, 2003
On the analysis of viral load endpoints in HIV vaccine trialsMichael G Hudgens, Antje Hoering, Steven G Self
Future Oncology (London, England)|April 12, 2017
End points and statistical considerations in immuno-oncology trials: impact on multiple myelomaAntje Hoering, Brian Durie, Hongwei Wang, et al.
Cancer Research|April 19, 2005
Experimental design and analysis of antibody microarrays: applying methods from cDNA arraysJeanette E Eckel-Passow, Antje Hoering, Terry M Therneau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120Madhav V Dhodapkar, Rachael Sexton, Antje Hoering, et al.
Haematologica|August 30, 2008
Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapyGuido Tricot, Bart Barlogie, Maurizio Zangari, et al.
Blood Advances|July 6, 2022
Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman diseaseFrits van Rhee, Adam Rosenthal, Karan Kanhai, et al.
Pageof 8